

Anastasia Ivanova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9250453/publications.pdf>

Version: 2024-02-01

86
papers

2,036
citations

304743

22
h-index

265206

42
g-index

92
all docs

92
docs citations

92
times ranked

1474
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimal Adaptive Designs for Binary Response Trials. <i>Biometrics</i> , 2001, 57, 909-913.	1.4	207
2	Minimizing predictability while retaining balance through the use of less restrictive randomization procedures. <i>Statistics in Medicine</i> , 2003, 22, 3017-3028.	1.6	207
3	Two-Dimensional Dose Finding in Discrete Dose Space. <i>Biometrics</i> , 2005, 61, 217-222.	1.4	117
4	Improved up-and-down designs for phase I trials. <i>Statistics in Medicine</i> , 2003, 22, 69-82.	1.6	116
5	A play-the-winner-type urn design with reduced variability. <i>Metrika</i> , 2003, 58, 1-13.	0.8	114
6	A New Dose-Finding Design for Bivariate Outcomes. <i>Biometrics</i> , 2003, 59, 1001-1007.	1.4	88
7	Cumulative cohort design for dose-finding. <i>Journal of Statistical Planning and Inference</i> , 2007, 137, 2316-2327.	0.6	83
8	Escalation, group and A + B designs for dose-finding trials. <i>Statistics in Medicine</i> , 2006, 25, 3668-3678.	1.6	68
9	Continuous Toxicity Monitoring in Phase II Trials in Oncology. <i>Biometrics</i> , 2005, 61, 540-545.	1.4	62
10	A non-parametric approach to the design and analysis of two-dimensional dose-finding trials. <i>Statistics in Medicine</i> , 2004, 23, 1861-1870.	1.6	55
11	Optimality, sample size, and power calculations for the sequential parallel comparison design. <i>Statistics in Medicine</i> , 2011, 30, 2793-2803.	1.6	52
12	Bivariate isotonic design for dose-finding with ordered groups. <i>Statistics in Medicine</i> , 2006, 25, 2018-2026.	1.6	47
13	Serum Calcification Propensity and Fetuin-A: Biomarkers of Cardiovascular Disease in Kidney Transplant Recipients. <i>American Journal of Nephrology</i> , 2018, 48, 21-31.	3.1	42
14	Convex Hull Test for Ordered Categorical Data. <i>Biometrics</i> , 1998, 54, 1541.	1.4	38
15	Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach. <i>Biometrics</i> , 2009, 65, 307-315.	1.4	38
16	A two-way enriched clinical trial design: combining advantages of placebo lead-in and randomized withdrawal. <i>Statistical Methods in Medical Research</i> , 2015, 24, 871-890.	1.5	31
17	Serum Uromodulin: A Biomarker of Long-Term Kidney Allograft Failure. <i>American Journal of Nephrology</i> , 2018, 47, 275-282.	3.1	31
18	Drawbacks to Integer Scoring for Ordered Categorical Data. <i>Biometrics</i> , 2001, 57, 567-570.	1.4	28

#	ARTICLE	IF	CITATIONS
19	A Phase I Study of Bortezomib in Combination With Standard 5-Fluorouracil and External-Beam Radiation Therapy for the Treatment of Locally Advanced or Metastatic Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2010, 9, 119-125.	2.3	27
20	PrecISE: Precision Medicine in Severe Asthma: An adaptive platform trial with biomarker ascertainment. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1594-1601.	2.9	27
21	Adaptive dose finding based on <i>t</i>-statistic for dose-“response trials. <i>Statistics in Medicine</i> , 2008, 27, 1581-1592.	1.6	24
22	When should the sequential parallel comparison design be used in clinical trials?. <i>Clinical Investigation</i> , 2013, 3, 823-833.	0.0	24
23	The Precision Interventions for Severe and/or Exacerbation-Prone (PrecISE) Asthma Network: An overview of Network organization, procedures, and interventions. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 488-516.e9.	2.9	24
24	Quality assessment of phase I dose-finding cancer trials: proposal of a checklist. <i>Clinical Trials</i> , 2008, 5, 478-485.	1.6	23
25	Impact of Hyperuricemia on Long-term Outcomes of Kidney Transplantation: Analysis of the FAVORIT Study. <i>American Journal of Kidney Diseases</i> , 2017, 70, 762-769.	1.9	22
26	Efficient generation of constrained block allocation sequences. <i>Statistics in Medicine</i> , 2008, 27, 1421-1428.	1.6	21
27	Defining the learning curve for successful staging with sentinel lymph node biopsy for endometrial cancer among surgeons at an academic institution. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 346-351.	2.5	21
28	Dose-finding designs for trials of molecularly targeted agents and immunotherapies. <i>Journal of Biopharmaceutical Statistics</i> , 2017, 27, 477-494.	0.8	19
29	An adaptive design for identifying the dose with the best efficacy/tolerability profile with application to a crossover dose-“finding study. <i>Statistics in Medicine</i> , 2009, 28, 2941-2951.	1.6	18
30	The rapid enrollment design for Phase I clinical trials. <i>Statistics in Medicine</i> , 2016, 35, 2516-2524.	1.6	17
31	Adaptive Designs for Clinical Trials with Highly Successful Treatments. <i>Drug Information Journal</i> , 2001, 35, 1087-1093.	0.5	16
32	Adjusting for observable selection bias in block randomized trials. <i>Statistics in Medicine</i> , 2005, 24, 1537-1546.	1.6	15
33	An Adaptive First in Man Dose-Escalation Study of NGX267: Statistical, Clinical, and Operational Considerations. <i>Journal of Biopharmaceutical Statistics</i> , 2009, 19, 247-255.	0.8	15
34	A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 1331-1337.	1.3	15
35	Nine-year change in statistical design, profile, and success rates of Phase II oncology trials. <i>Journal of Biopharmaceutical Statistics</i> , 2016, 26, 141-149.	0.8	15
36	Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2129-2135.	2.0	14

#	ARTICLE	IF	CITATIONS
37	Sequential parallel comparison design with binary and time-to-event outcomes. <i>Statistics in Medicine</i> , 2018, 37, 1454-1466.	1.6	14
38	Adaptive Tests for Ordered Categorical Data. <i>Journal of Modern Applied Statistical Methods</i> , 2002, 1, 269-280.	0.2	14
39	Two-stage designs for Phase 2 dose-finding trials. <i>Statistics in Medicine</i> , 2012, 31, 2872-2881.	1.6	13
40	Chemotherapy Following PD-1 Inhibitor Blockade in Patients with Unresectable Stage III/Stage IV Metastatic Melanoma: A Single Academic Institution Experience. <i>Oncology</i> , 2020, 98, 174-178.	1.9	13
41	Comparison of Isotonic Designs for Dose-Finding. <i>Statistics in Biopharmaceutical Research</i> , 2009, 1, 101-107.	0.8	12
42	Practical designs for Phase I combination studies in oncology. <i>Journal of Biopharmaceutical Statistics</i> , 2016, 26, 150-166.	0.8	12
43	Phase Ib Study of Bavituximab With Carboplatin and Pemetrexed in Chemotherapy-Naive Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, e481-e487.	2.6	12
44	A phase I evaluation of the effect of curcumin on dose-limiting toxicity and pharmacokinetics of irinotecan in participants with solid tumors. <i>Clinical and Translational Science</i> , 2022, 15, 1304-1315.	3.1	12
45	The use of the triangular test with response-adaptive treatment allocation. <i>Statistics in Medicine</i> , 2005, 24, 1483-1493.	1.6	11
46	The precision interventions for severe and/or exacerbation-prone asthma (PreClSE) adaptive platform trial: statistical considerations. <i>Journal of Biopharmaceutical Statistics</i> , 2020, 30, 1026-1037.	0.8	11
47	Dose-Finding in Oncology—Nonparametric Methods. , 2006, , 49-58.		10
48	Donor lymphocyte infusion and methotrexate for immune recovery after T-cell depleted haploidentical transplantation. <i>American Journal of Hematology</i> , 2018, 93, 169-178.	4.1	9
49	Response-adaptive designs for continuous outcomes. <i>Journal of Statistical Planning and Inference</i> , 2006, 136, 1845-1852.	0.6	8
50	A phase 1b/2 study of CD30-specific chimeric antigen receptor T-cell (CAR-T) therapy in combination with bendamustine in patients with CD30+ Hodgkin and non-Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS3095-TPS3095.	1.6	8
51	Sequential urn designs with elimination for comparing $K \times T$ treatments. <i>Statistics in Medicine</i> , 2005, 24, 1995-2009.	1.6	7
52	Futility stopping in clinical trials, optimality and practical considerations. <i>Journal of Biopharmaceutical Statistics</i> , 2020, 30, 1050-1059.	0.8	7
53	A Two-cohort Phase I Study of Weekly Oxaliplatin and Gemcitabine, Then Oxaliplatin, Gemcitabine, and Erlotinib During Radiotherapy for Unresectable Pancreatic Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 250-253.	1.3	6
54	Dose finding with continuous outcome in phase I oncology trials. <i>Pharmaceutical Statistics</i> , 2015, 14, 102-107.	1.3	6

#	ARTICLE	IF	CITATIONS
55	Permutation and Bootstrap Testing for the Sequential Parallel Comparison Design. <i>Statistics in Biopharmaceutical Research</i> , 2019, 11, 44-51.	0.8	6
56	Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922). <i>Melanoma Research</i> , 2021, 31, 162-172.	1.2	6
57	Monitoring rules for toxicity in Phase II oncology trials. <i>Clinical Investigation</i> , 2015, 5, 373-381.	0.0	5
58	Multi-stage adaptive enrichment trial design with subgroup estimation. <i>Journal of Biopharmaceutical Statistics</i> , 2020, 30, 1038-1049.	0.8	5
59	Dose finding when the target dose is on a plateau of a dose-response curve: comparison of fully sequential designs. <i>Pharmaceutical Statistics</i> , 2013, 12, 309-314.	1.3	4
60	Dose Finding With the Sequential Parallel Comparison Design. <i>Journal of Biopharmaceutical Statistics</i> , 2014, 24, 1091-1101.	0.8	4
61	Estimating the subgroup and testing for treatment effect in a post-hoc analysis of a clinical trial with a biomarker. <i>Journal of Biopharmaceutical Statistics</i> , 2019, 29, 685-695.	0.8	4
62	Efficient designs for phase II oncology trials with ordinal outcome. <i>Statistics and Its Interface</i> , 2012, 5, 463-469.	0.3	4
63	Can sequential parallel comparison design and two-way enriched design be useful in medical device clinical trials?. <i>Journal of Biopharmaceutical Statistics</i> , 2016, 26, 167-177.	0.8	3
64	Randomization-based analysis of covariance for inference in the sequential parallel comparison design. <i>Journal of Biopharmaceutical Statistics</i> , 2019, 29, 696-713.	0.8	3
65	Power calculations for the sequential parallel comparison design with continuous outcomes. <i>Journal of Biopharmaceutical Statistics</i> , 2020, 30, 1121-1129.	0.8	3
66	Two-stage design for phase II oncology trials with relaxed futility stopping. <i>Statistics and Its Interface</i> , 2016, 9, 93-98.	0.3	3
67	Urn designs with immigration: Useful connection with continuous time stochastic processes. <i>Journal of Statistical Planning and Inference</i> , 2006, 136, 1836-1844.	0.6	2
68	Enrollment and Stopping Rules for Managing Toxicity Requiring Long Follow-Up in Phase II Oncology Trials. <i>Journal of Biopharmaceutical Statistics</i> , 2015, 25, 1206-1214.	0.8	2
69	Higher order response-adaptive urn designs for clinical trials with highly successful treatments. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2015, 64, 175-189.	1.0	2
70	Sample size re-estimation and other midcourse adjustments with sequential parallel comparison design. <i>Journal of Biopharmaceutical Statistics</i> , 2017, 27, 416-425.	0.8	2
71	Selection of the initial design for the two-stage continual reassessment method. <i>Journal of Biopharmaceutical Statistics</i> , 2017, 27, 495-506.	0.8	2
72	Consistency of the CRM when the dose-toxicity curve is not monotone and its application to the POCRM. <i>Statistics in Medicine</i> , 2021, 40, 2073-2082.	1.6	2

#	ARTICLE	IF	CITATIONS
73	The properties of entropy as a measure of randomness in a clinical trial. Journal of Statistical Planning and Inference, 2022, 216, 182-193.	0.6	2
74	Adaptive isotonic estimation of the minimum effective and peak doses in the presence of covariates. Journal of Statistical Planning and Inference, 2012, 142, 1899-1907.	0.6	1
75	Advances in Statistical Approaches to Oncology Drug Development. Therapeutic Innovation and Regulatory Science, 2014, 48, 81-89.	1.6	1
76	Methods for clarifying criteria for study continuation at interim analysis. Pharmaceutical Statistics, 2020, 19, 720-732.	1.3	1
77	Phase I Clinical Trials. , 0, , 1-14.		0
78	Letter to the Editor. Journal of Biopharmaceutical Statistics, 2013, 23, 709-710.	0.8	0
79	Comment. Statistics in Biopharmaceutical Research, 2015, 7, 357-358.	0.8	0
80	Rapid enrollment design for finding the optimal dose in immunotherapy trials with ordered groups. Journal of Biopharmaceutical Statistics, 2019, 29, 625-634.	0.8	0
81	Guest editorsâ€™ note on the special issue innovative design and analysis of complex clinical trials. Journal of Biopharmaceutical Statistics, 2020, 30, 947-947.	0.8	0
82	Continual reassessment method with regularization in phase I clinical trials. Journal of Biopharmaceutical Statistics, 2020, 30, 964-978.	0.8	0
83	Response-Adaptive Designs. , 2010, , 1157-1161.		0
84	Response-Adaptive Designs. , 2012, , 1157-1161.		0
85	Blood-based biomarkers in metastatic colorectal cancer patients treated with FOLFIRI plus regorafenib or placebo: Results from LCCC1029.. Journal of Clinical Oncology, 2019, 37, 587-587.	1.6	0
86	Phase Ib trial of lenalidomide as post-remission therapy for older adults with acute myeloid leukemia: Safety and longitudinal assessment of geriatric functional domains. Journal of Geriatric Oncology, 2021, , .	1.0	0